2015 Research Annual Report

Rheumatology

Tocilizumab Shown to be Safe and Effective as Novel Treatment for Children with Juvenile Idiopathic Arthritis

Children with polyarticular juvenile idiopathic arthritis (JIA) can now be treated safely and effectively with tocilizumab, an interleukin-6 receptor inhibitor drug, according to a 58-center global study coordinated and co-designed at Cincinnati Children’s.